In April 2026, COMPASS Pathways announced that the FDA granted a rolling NDA review for its synthetic psilocybin therapy COMP360 in treatment-resistant depression and selected it for the ...
Some psychedelic drugs, once considered fringe, are getting a step closer to possibly being approved for use as mental health treatments in the United States.
1monon MSN
The FDA just fast-tracked psychedelic drugs to treat depression. They could be here by this summer
The agency issued priority vouchers for 3 experimental new drugs using psilocybin and methylone, amid Trump’s pro-psychedelics push. The Trump administration is putting America on the fast track to a ...
WASHINGTON (AP) — The Food and Drug Administration said Friday it will offer ultra-fast review to three psychedelic drugs being developed to treat mental health conditions, including depression, the ...
The US Food and Drug Administration (FDA) will convene a public hearing intended to obtain feedback on its Commissioner's National Priority Voucher (CNPV) pilot programme, a framework that has ...
The new income categories, which kicked in for the 2026-27 school year, aimed at prioritizing Tennessee’s low-income families ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results